Single dose oral lornoxicam for acute postoperative pain in adults

Scolaris Content Display Scolaris Content Display

Ir a:

Figure 1

Forest plot of comparison: 3 Lornoxicam versus placebo, outcome: 3.1 Participants with at least 50% pain relief over 6 hours.

Analysis 1.1

Comparison 1 Lornoxicam versus placebo, Outcome 1 Participants with at least 50% pain relief over 6 hours.

Analysis 1.2

Comparison 1 Lornoxicam versus placebo, Outcome 2 Participants with any adverse event.

Table 1. Summary of outcomes: analgesia and rescue medication

		Analgesia			Rescue medication
Study ID	Treatment	PI or PR	Number with 50% PR	PGE: v good or excellent	Median time to use (h)	% using
Moller 2008	(1) Lornoxicam 8 mg SR, n = 80 (2) Lornoxicam 8 mg QR, n = 80 (3) Placebo, n = 40	TOTPAR 6: (1) 8.1 (2) 11.3 (3) 1.8	(1) 27/80 (2) 41/80 (3) 0/40	No usable data	(1) 4.0 (2) 5.7 (3) 1.1	at 8 h: (1) 48/80 (2) 50/80 (3) 37/40
Norholt 1995	(1) Lornoxicam 4 mg, n = 43 (2) Lornoxicam 8 mg, n = 45 (3) Lornoxicam 16 mg, n = 48 (4) Lornoxicam 32 mg, n = 48 (5) Ketorolac 10 mg, n = 46 (6) Placebo, n = 48	TOTPAR 6: (1) 9.6 (2) 13.7 (3) 15.0 (4) 17.7 (6) 3.7	(1) 18/43 (2) 29/45 (3) 34/48 (4) 42/48 (6) 4/48	(1) 12/43 (2) 23/45 (3) 27/48 (4) 32/48 (5) 25/46 (6) 4/48	Mean: (1) 3.1 (2) 4.1 (3) 4.9 (4) 5.1 (6) 1.7	No data
Patel 1991	(1) Lornoxicam 2 mg, n = 30 (2) Lornoxicam 4 mg, n = 30 (3) Lornoxicam 8 mg, n = 30 (4) Aspirin 650 mg, n = 30 (6) Placebo, n = 30	TOTPAR 6: (1) 8.43 (2) 8.99 (3) 11.12 (5) 7.38	(1) 11/30 (2) 11/30 (3) 15/30 (5) 9/30	No usable data	No data	No data
QR ‐ quick release; SR ‐ slow release

Table 1. Summary of outcomes: analgesia and rescue medication

Table 2. Summary of outcomes: adverse events and withdrawals

		Adverse events		Withdrawals
Study ID	Treatment	Any	Serious	Adverse event	Other
Moller 2008	(1) Lornoxicam 8 mg SR, n = 80 (2) Lornoxicam 8 mg QR, n = 80 (3) Placebo, n = 40	at 7 days: (1) 39/80 (2) 43/80 (3) 14/40	None	None	None
Norholt 1995	(1) Lornoxicam 4 mg, n = 43 (2) Lornoxicam 8 mg, n = 45 (3) Lornoxicam 16 mg, n = 48 (4) Lornoxicam 32 mg, n = 48 (5) Ketorolac 10 mg, n = 46 (6) Placebo, n = 48	No usable data	None reported	None	None
Patel 1991	(1) Lornoxicam 2 mg, n = 30 (2) Lornoxicam 4 mg, n = 30 (3) Lornoxicam 8 mg, n = 30 (4) Aspirin 650 mg, n = 30 (6) Placebo, n = 30	at 8 h: (1) 3/30 (2) 1/30 (3) 2/30 (4) 2/30 (5) 2/30	None	None	None
QR ‐ quick release; SR ‐ slow release

Table 2. Summary of outcomes: adverse events and withdrawals

Comparison 1. Lornoxicam versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Participants with at least 50% pain relief over 6 hours Show forest plot	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

1.1 Lornoxicam 4 mg	2	151	Risk Ratio (M‐H, Fixed, 95% CI)	2.35 [1.33, 4.14]
1.2 Lornoxicam 8 mg	3	273	Risk Ratio (M‐H, Fixed, 95% CI)	4.69 [2.70, 8.12]
2 Participants with any adverse event Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

2.1 Lornoxicam 2 to 8 mg	2	320	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [0.92, 2.17]
2.2 Lornoxicam 8 mg	2	260	Risk Ratio (M‐H, Fixed, 95% CI)	1.43 [0.92, 2.21]

Comparison 1. Lornoxicam versus placebo